Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:SNG
- CUSIP: N/A
- Web: www.synairgen.com/
- Market Cap: £7.77 million
- Outstanding Shares: 91,362,000
- 50 Day Moving Avg: GBX 9.09
- 200 Day Moving Avg: GBX 17.76
- 52 Week Range: GBX 7 - GBX 37.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.05 per share
- Price / Book: 1.70
- EBIDTA: ($3,410,000.00)
- Return on Equity: -53.32%
- Return on Assets: -46.48%
- Average Volume: 251,399 shs.
Frequently Asked Questions for Synairgen plc (LON:SNG)
What is Synairgen plc's stock symbol?
Synairgen plc trades on the London Stock Exchange (LON) under the ticker symbol "SNG."
When will Synairgen plc make its next earnings announcement?
Where is Synairgen plc's stock going? Where will Synairgen plc's stock price be in 2017?
1 brokerages have issued 12 month target prices for Synairgen plc's shares. Their forecasts range from GBX 46 to GBX 137. On average, they anticipate Synairgen plc's stock price to reach GBX 91.50 in the next year. View Analyst Ratings for Synairgen plc.
Who are some of Synairgen plc's key competitors?
Some companies that are related to Synairgen plc include RXi Pharmaceuticals Corporation (RXII), OncoGenex Pharmaceuticals (OGXI), Roka Bioscience (ROKA), Jaguar Animal Health (JAGX), Transgenomic (PRPO), Repros Therapeutics (RPRX), Akers Biosciences (AKR), Ixico Plc (IXI), Metabolix (YTEN), Ampliphi Biosciences Corp (APHB), Rosetta Genomics (ROSG), Prana Biotechnology Ltd (PRAN), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Caladrius Biosciences (CLBS), Celator Pharmaceuticals (CPXX), Cellular Dynamics International (ICEL) and Covance (CVD).
Who are Synairgen plc's key executives?
Synairgen plc's management team includes the folowing people:
- John Ward, Finance Director, Executive Director, Secretary
- Phillip Monk, Chief Scientific Officer, Executive Director
- Richard Marsden, Chief Executive Officer, Executive Director
- Simon Shaw, Non-Executive Chairman of the Board
- Iain Buchanan, Non-Executive Director
- Bruce L Campbell, Non-Executive Director
- Paul Hugh Anthony Clegg, Non-Executive Director
- Stephen Holgate CBE, Non-Executive Director
How do I buy Synairgen plc stock?
Shares of Synairgen plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Synairgen plc's stock price today?
MarketBeat Community Rating for Synairgen plc (LON SNG)MarketBeat's community ratings are surveys of what our community members think about Synairgen plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Synairgen plc stock can currently be purchased for approximately GBX 8.50.
Consensus Ratings for Synairgen plc (LON:SNG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 91.50|
Analysts' Ratings History for Synairgen plc (LON:SNG)
(Data available from 7/25/2015 forward)
|9/22/2016||N+1 Singer||Lower Price Target||Buy||GBX 47 -> GBX 46|
Earnings History for Synairgen plc (LON:SNG)Earnings History by Quarter for Synairgen plc (LON SNG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Synairgen plc (LON:SNG)
Current Year EPS Consensus Estimate: $-4.12 EPS
Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Synairgen plc (LON:SNG)Insider Trades by Quarter for Synairgen plc (LON:SNG)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/11/2015||Shaw,Simon J B||Insider||Buy||65,217||GBX 23||£14,999.91|
Headline Trends for Synairgen plc (LON:SNG)
Latest Headlines for Synairgen plc (LON:SNG)
Synairgen plc (SNG) Chart for Tuesday, July, 25, 2017